Lumida
/JAZZ
⌘K
Jazz Pharmaceuticals PLC

Jazz Pharmaceuticals PLC

JAZZ
$245.80USD+2.21%+5.32 today

MARKET CAP

16.0B

P/E (TTM)

2,234.5x

FWD P/E

DAY RANGE

$244 – $247

52W RANGE

$124
$266

AI Summary

Stalk
TrimMedium

JAZZ remains in a corrective structural repair phase after failing beneath the 9-EMA, 20-EMA, and 50-SMA, with a bearish pivot point confirming downside control. A minor exhaustion wick hints at a possible relief bounce, but any rally into the moving averages is likely to stall, reinforcing a medium-term bearish bias. Exposure should be trimmed now, awaiting a better entry on a clear stabilization or reclaim of key averages, while acknowledging that the long-term uptrend above the 200-SMA remains intact.

  • Q2 revenue hit $1.2B (+16% YoY), with ZyWave at $471M (+13%).
  • Epidiolex achieved blockbuster status, delivering $292M in Q2 and $1.1B expected in 2025.
  • High-sodium generics may erode ZyWave volumes as payers tighten utilization.
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$3.1B$3.7B$3.8B$4.1B$4.3B
YoY %+30.9%+18.3%+4.8%+6.1%+4.9%
P / Sales2.5x2.7x2.4x2.0x2.4x
EV / Sales5.0x4.5x4.0x3.4x3.8x
Gross Profit, Adj.$2.7B$3.1B$3.4B$3.6B$3.8B
YoY %+19.8%+17.5%+9.0%+6.6%+3.9%
Margin %85.8%85.2%88.6%89.0%88.2%
EV / Gross Profit5.8x5.3x4.5x3.8x4.3x
EBITDA, Adj.$722.8M$1.1B$1.2B$1.4B$1.2B
YoY %-30.8%+58.0%+8.3%+12.2%-12.5%
Margin %23.4%31.2%32.2%34.1%28.4%
EV / EBITDA21.2x14.6x12.4x9.8x13.4x
EBIT$170.3M$-65.5M$578.6M$716.6M$-430.2M
YoY %-55.0%-138.5%+983.0%+23.9%-160.0%
Margin %5.5%-1.8%15.1%17.6%-10.1%
EV / EBIT90.1x-254.0x26.4x19.0x-37.9x
Net Income$-329.7M$-224.1M$414.8M$560.1M$-356.1M
YoY %-238.2%+32.0%+285.1%+35.0%-163.6%
Net Margin-10.7%-6.1%10.8%13.8%-8.3%
EPS (GAAP)-$5.52-$3.58$6.10$8.65-$5.84
YoY %-230.8%+35.1%+270.4%+41.8%-167.5%